|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.51 AUD | -3.77% |
|
-20.31% | -10.53% |
| 05-28 | Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD | CI |
| 05-28 | Opthea Completes Enrollments in COAST, ShORe Trials | MT |
Opthea Limited reported earnings results for the half year ended December 31, 2021. For the half year, the company reported sales was USD 0.091218 million compared to USD 0.19784 million a year ago. Net loss was USD 37.71 million compared to USD 25.73 million a year ago.
Basic loss per share from continuing operations was USD 0.1074 compared to USD 0.0908 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -10.53% | 224M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
OPTHEA LIMITED 
